<DOC>
	<DOCNO>NCT00379236</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind study perform approximately 600 subject chronic idiopathic osteoarthritis ( OA ) knee . An open-label safety extension follow .</brief_summary>
	<brief_title>A Study Efficacy Safety EUFLEXXA™ Treatment Painful Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>1 . Chronic OA target knee confirm ACR Criteria 2 . Pain due OA target knee present least 6 month : • Moderate severe pain score 41 mm 90 mm record 100 mm VAS immediately follow 50foot walk 3 . A bilateral standing AP Xray confirm OA target knee—obtained within 6month period prior Screening Visit—and grade 2 3 accord Kellgren Lawrence Grading Scale 4 . Ability willingness use acetaminophen analgesic ( rescue ) study medication The acetaminophen dose must exceed 4 grams/day ( 4000 mg ) If subject know chronic liver disease , maximum dose acetaminophen must exceed 2 grams/day ( 2000 mg ) The subject must willing able discontinue acetaminophen least 24 hour prior studyspecific visit The study specific acetaminophen provide used knee pain . 5 . Ability perform procedure require pain index evaluation ( unassisted walk 50 foot flat surface go stair ) . 6 . Willingness ability complete efficacy safety questionnaires ability read understand study instruction 7 . Signed studyspecific Subject Informed Consent Form 1 . Any major injury ( include sport injury ) target knee within 12 month prior Screening Visit 2 . Any surgery target knee within 12 month prior Screening Visit , surgery contralateral knee weightbearing joint interfere knee assessment 3 . Prior articular procedure , transplant ligament reconstruction target knee 4 . Inflammatory arthropathy rheumatoid arthritis , lupus arthropathy , psoriatic arthritis 5 . Gout calcium pyrophosphate ( pseudogout ) diseases flare within previous 6 month prior Screening Visit 6 . Xray finding acute fracture , severe loss bone density , avascular necrosis , and/or severe bone joint deformity target knee 7 . Osteonecrosis either knee 8 . Fibromyalgia , pes anserine bursitis , lumbar radiculopathy , and/or neurogenic vascular claudication 9 . Significant anterior knee pain due diagnose isolated patellafemoral syndrome chondromalacia target knee 10 . Significant target knee joint infection skin disorder/infection within previous 6 month prior study enrollment 11 . Symptomatic OA hip , spine , ankle , would interfere evaluation target knee 12 . Known hypersensitivity acetaminophen , EUFLEXXA™ , Phosphate buffer saline solution 13 . Women childbearing potential pregnant , nursing , plan become pregnant , agree remain acceptable method birth control throughout entire study period 14 . Recurrent medical history severe allergic immunemediated reaction immune disorder 15 . Vascular insufficiency lower limbs peripheral neuropathy severe enough interfere study evaluation 16 . Current treatment treatment within previous 2 year prior Screening Visit malignancy unless specific write permission provide Sponsor ( exclude basal cell squamous cell carcinoma skin ) 17 . Active liver disease base liver profile AST , ALT , conjugate bilirubin &gt; 2 time upper limit normal 18 . Renal insufficiency base serum creatinine &gt; 2.0 mg/dL 19 . Any clinically significant laboratory value base clinical history Investigator feel may affect study evaluation 20 . Any intercurrent chronic disease condition may interfere completion 6month ( 12month ) followup study , liver disease , severe coronary disease , drug abuse , disorder mental state , clinically significant condition 21 . Current alcoholism , and/or know current addiction pain medication 22 . Any clinically significant find would place patient health risk , impact study , affect completion study 23 . Any psychiatric illness would prevent comprehension detail nature study 24 . Participation experimental drug device study within 6 month prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>knee</keyword>
</DOC>